Platelet-derived growth factor-induced severe and chronic vasoconstriction of cerebral arteries: Proposed growth factor explanation of cerebral vasospasm

Neurosurgery

Volumn 66, Issue 4, 2010, Pages 728-735

  Zhang, Zhi Wen ^a,b   Yanamoto, Hiroji ^a,c   Nagata, Izumi ^d   Miyamoto, Susumu ^a   Nakajo, Yukako ^a,e   Xue, Jing Hui ^a,b   Iihara, Koji ^a   Kikuchi, Haruhiko ^a  

^a NATIONAL CEREBRAL AND CARDIOVASCULAR CENTER   (Japan)

^b First Affiliated Hospital   (China)

^c OSAKA UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

^d NAGASAKI UNIVERSITY   (Japan)

^e RAKUWAKAI OTOWA HOSPITAL   (Japan)

Author keywords

Cerebral vasospasm; Complement factor; Growth factor; Macrophage

Indexed keywords

RECOMBINANT PLATELET DERIVED GROWTH FACTOR BB; TRAPIDIL; VASCULOTROPIN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BASILAR ARTERY; BRAIN ANGIOGRAPHY; BRAIN ARTERY; BRAIN VASOSPASM; CONTINUOUS INFUSION; CONTROLLED STUDY; DIGITAL SUBTRACTION ANGIOGRAPHY; DISEASE SEVERITY; DRUG DOSE COMPARISON; MALE; NONHUMAN; PRIORITY JOURNAL; RABBIT; TREATMENT OUTCOME; VASOCONSTRICTION;

ANIMALS; CEREBRAL ANGIOGRAPHY; CEREBRAL ARTERIES; DISEASE MODELS, ANIMAL; DOSE-RESPONSE RELATIONSHIP, DRUG; MALE; PLATELET-DERIVED GROWTH FACTOR; RABBITS; SUBARACHNOID HEMORRHAGE; TIME FACTORS; TRAPIDIL; VASOCONSTRICTION; VASODILATOR AGENTS; VASOSPASM, INTRACRANIAL;

EID: 77949976466     PISSN: 0148396X     EISSN: None     Source Type: Journal    
DOI: 10.1227/01.NEU.0000366111.08024.26     Document Type: Article

References (53)

1. Komotar RJ, Zacharia BE, Valhora R, Mocco J, Connolly ES Jr. Advances in vasospasm treatment and prevention. J Neurol Sci. 2007;261(1-2):134-142.
2. Mocco J, Zacharia BE, Komotar RJ, Connolly ES Jr. A review of current and future medical therapies for cerebral vasospasm following aneurysmal subarachnoid hemorrhage. Neurosurg Focus. 2006;21(3):E9.
3. Sercombe R, Dinh YR, Gomis P. Cerebrovascular inflammation following subarachnoid hemorrhage. Jpn J Pharmacol. 2002;88(3):227-249.
4. Zhang Z, Nagata I, Kikuchi H, et al. Broad-spectrum and selective serine protease inhibitors prevent expression of platelet-derived growth factor-BB and cerebral vasospasm after subarachnoid hemorrhage: vasospasm caused by cisternal injection of recombinant platelet-derived growth factor-BB. Stroke. 2001;32(7):1665-1672.
5. Suzuki M, Ogawa A, Sakurai Y, et al. Thrombin activity in cerebrospinal fluid after subarachnoid hemorrhage. Stroke. 1992;23:1181-1182.
6. Kasuya H, Shimizu T. Activated complement components C3a and C4a in cerebrospinal fluid and plasma following subarachnoid hemorrhage. J Neurosurg. 1989;71(5 pt 1):741-746.
7. Yanamoto H, Kikuchi H, Okamoto S, Nozaki K. Preventive effect of synthetic serine protease inhibitor, FUT-175, on cerebral vasospasm in rabbits. Neurosurgery. 1992;30(3):351-356.
8. Tsurutani H, Ohkuma H, Suzuki S. Effects of thrombin inhibitor on thrombinrelated signal transduction and cerebral vasospasm in the rabbit subarachnoid hemorrhage model. Stroke. 2003;34(6):1497-1500.
9. Yanamoto H, Kikuchi H, Sato M, Shimizu Y, Yoneda S, Okamoto S. Therapeutic trial of cerebral vasospasm with the serine protease inhibitor, FUT-175, administered in the acute stage after subarachnoid hemorrhage. Neurosurgery. 1992;30(3):358-363.
10. Jerius H, Beall A, Woodrum D, Epstein A, Brophy C. Thrombin-induced vasospasm: cellular signaling mechanisms. Surgery. 1998;123(1):46-50.
11. Nelken NA, Soifer SJ, O,Keefe J, Vu TK, Charo IF, Coughlin SR. Thrombin receptor expression in normal and atherosclerotic human arteries. J Clin Invest. 1992;90(4): 1614-1621.
12. Maeda Y, Hirano K, Kai Y, et al. Up-regulation of proteinase-activated receptor 1 and increased contractile responses to thrombin after subarachnoid haemorrhage. Br J Pharmacol. 2007;152(7):1131-1139.
13. Hirashima Y, Nakamura S, Suzuki M, et al. Cerebrospinal fluid tissue factor and thrombin-antithrombin ? complex as indicators of tissue injury after subarachnoid hemorrhage. Stroke. 1997;28(9):1666-1670.
14. Yanamoto H, Kikuchi H, Okamoto S, Nozaki K. Cerebral vasospasm caused by cisternal injection of polystyrene latex beads in rabbits is inhibited by a serine protease inhibitor. Surg Neurol. 1994;42(5):374-381.
15. Lappegård KT, Bergseth G, Riesenfeld J, et al. The artificial surface-induced whole blood inflammatory reaction revealed by increases in a series of chemokines and growth factors is largely complement dependent. J Biomed Mater Res A. 2008;87(1): 129-135.
16. Andrae J, Gallini R, Betsholtz C. Role of platelet-derived growth factors in physiology and medicine. Genes Dev. 2008;22(10):1276-1312.
17. Benzaquen LR, Nicholson-Weller A, Halperin JA. Terminal complement proteins C5b-9 release basic fibroblast growth factor and platelet-derived growth factor from endothelial cells. J Exp Med. 1994;179(3):985-992.
18. Ross R, Masuda J, Raines EW, et al. Localization of PDGF-B protein in macrophages in all phases of atherogenesis. Science. 1990;248(4958):1009-1012.
19. Shimokado K, Raines EW, Madtes DK, Barrett TB, Benditt EP, Ross R. A significant part of macrophage-derived growth factor consists of at least two forms of PDGF. Cell. 1985;43(1):277-286.
20. Böhm M, Blasius S, Roessner A. Immunohistochemical localization of PDGF B, PDGF beta receptors and IGF I receptors during atherogenesis. Zentralbl Pathol. 1994;140(4-5):357-362.
21. Raines EW, Bowen-Pope DF, Ross R. Handbook of Experimental Pharmacology, Vol.95/I PeptiDeGrowth Factors and Their Receptors I, Platelet-derived growth factor. In: Sporn MB, Roberts AB, eds. Berlin Heidelberg: Springer-Verlag; 1990:173-262.
22. Gaetani P, Tancioni F, Grignani G, et al. Platelet derived growth factor and subarachnoid haemorrhage: a study on cisternal cerebrospinal fluid. Acta Neurochir (Wien). 1997;139(4):319-324.
23. Berk BC, AlexanDerRW, Brock TA, Gimbrone MA Jr, Webb RC. Vasoconstriction: a new activity for platelet-derived growth factor. Science. 1986;232(4746):87-90.
24. Sachinidis A, Locher R, Hoppe J, Vetter W. The platelet-derived growth factor isomers, PDGF-AA, PDGF-AB and PDGF-BB, induce contraction of vascular smooth muscle cells by different intracellular mechanisms. FEBS Lett. 1990;275(1-2):95-98.
25. Bassett JE, Bowen-Pope DF, Takayasu M, Dacey RG Jr. Platelet-derived growth factor does not constrict rat intracerebral arterioles in vitro. Microvasc Res. 1988;35(3): 368-373.
26. Gesualdo L, Di Paolo S, Ranieri E, Schena FP. Trapidil inhibits human mesangial cell proliferation: effect on PDGF beta-receptor binding and expression. Kidney Int. 1994;46(4):1002-1009.
27. Suzuki Y, Yamaguchi K, Shimada S, Kitamura Y, Ohnishi H. Antithrombotic activity and the mechanism of action of trapidil (Rocornal® ). Prostaglandins Leukot Med. 1982;9(6):685-695.
28. Nagata I, Zhang Z, Sawada M, Hashimoto N, Kikuchi H, Yanamoto H. Systemically administered thrombin inhibitors can prevent neointimal formation and cerebral vasospasm: the possible role of thrombin and PDGF-BB in vascular pathogeneses. In: Kikuchi H (ed). Strategic Medical Science Against Brain Attack. Tokyo: Springer-Verlag; 2002:234-253.
29. Sakata M, Yanamoto H, Hashimoto N, et al. Induction of infarct tolerance by platelet-derived growth factor against temporary focal ischemia. Brain Res. 1998;784(1- 2):250-255.
30. Liu MW, Roubin GS, Robinson KA, et al. Trapidil in preventing restenosis after balloon angioplasty in the atherosclerotic rabbit. Circulation. 1990;81(3):1089-1093.
31. Matsuno H, Stassen JM, Hoylaerts MF, Vermylen J, Deckmyn H. Fast and reproducible vascular neointima formation in the hamster carotid artery: effects of trapidil and captopril. Thromb Haemost. 1995;74(6):1591-1596.
32. Badgett A, Bonner JC, Brody AR. Interferon-gamma modulates lung macrophage production of PDGF-BB and fibroblast growth. J Lipid Mediat Cell Signal. 1996;13(1):89-97.
33. Antoniades HN, Galanopoulos T, Neville-GolDen J, Kiritsy CP, Lynch SE. Injury induces in vivo expression of platelet-derived growth factor (PDGF) and PDGF receptor mRNAs in skin epithelial cells and PDGF mRNA in connective tissue fibroblasts. Proc Natl Acad Sci U S A. 1991;88(2):565-569.
34. Yanamoto H, Kikuchi H, Ishikawa J, et al. Intravenous FUT-175 inhibits complement activation in the cerebrospinal fluid and vasospasm-related delayed ischemic neurological deficit following subarachnoid hemorrhage. In: J. Max Findlay (ed). Cerebral Vasospasm. Elsevier Science Publishers BV; 1993:431-434.
35. Deleted in proof.
36. Mack WJ, Ducruet AF, Hickman ZL, et al. Early plasma complement C3a levels correlate with functional outcome after aneurysmal subarachnoid hemorrhage. Neurosurgery. 2007;61(2):255-260.
37. Kamiyama M, Utsunomiya K, Taniguchi K, et al. Contribution of Rho A and Rho kinase to platelet-derived growth factor-BB-induced proliferation of vascular smooth muscle cells. J Atheroscler Thromb. 2003;10(2):117-123.
38. Ishikura K, Fujita H, Hida M, Awazu M. Trapidil inhibits platelet-derived growth factor-induced migration via protein kinase A and RhoA/Rho-associated kinase in rat vascular smooth muscle cells. Eur J Pharmacol. 2005;515(1-3):28-33.
39. Liao JK, Seto M, Noma K. Rho kinase (ROCK) inhibitors. J Cardiovasc Pharmacol. 2007;50(1):17-24.
40. Shimokawa H, Rashid M. Development of Rho-kinase inhibitors for cardiovascular medicine. Trends Pharmacol Sci. 2007;28(6):296-302.
41. Shimokawa H, Seto M, Katsumata N, et al. Rho-kinase-mediated pathway induces enhanced myosin light chain phosphorylations in a swine model of coronary artery spasm. Cardiovasc Res. 1999;43(4):1029-1039.
42. Maeda Y, Hirano K, Hirano M, et al. Enhanced contractile response of the basilar artery to platelet-derived growth factor in subarachnoid hemorrhage. Stroke. 2009;40(2):591-596.
43. Sato M, Tani E, Fujikawa H, Kaibuchi K. Involvement of Rho-kinase-mediated phosphorylation of myosin light chain in enhancement of cerebral vasospasm. Circ Res. 2000;87(3):195-200.
44. Miller CA, Lombard FW, Wu CT, et al. Role of vascular mitogens in subarachnoid hemorrhage-associated cerebral vasculopathy. Neurocrit Care. 2006;5(3):215-221.
45. Vieweg U, Schramm J, Urbach H. Platelet-derived growth factor (PDGF-AB) like immune reactivity in serum and in cerebral spinal fluid following experimental subarachnoid haemorrhage in dogs. Acta Neurochir (Wien). 1999;141(8):861-865.
46. Bagdatoglu C, Guleryuz A, Unlu A, et al. Resolution of cerebral vasospasm with trapidil; an animal model. J Clin Neurosci. 2002;9(4):429-432.
47. Inoue K, Kuwaki K, Ueda K, Honnma S, Shirai T, Watanabe F. Intravenous trapidil, MDR-1871 Phase I study. Igaku-to-Yakugaku. 1982;7(3):795-810.
48. Hirayama A, Kodama K, Yui Y, et al. Effect of trapidil on cardiovascular events in patients with coronary artery disease (results from the Japan Multicenter Investigation for Cardiovascular Diseases-Mochida [JMIC-M]). Am J Cardiol. 2003;92(7):789-793.
49. Ito C, Hayashi Y, Seo T, Ohnishi H, Yazima G. Toxicological studies of trapymin. Acute and subacute toxicity studies of trapymin in mice and rats. Iyakuhin Kenkyu. 1976.; 7(2):161-169.
50. Yasue H, Ogawa H, Tanaka H, et al. Effects of aspirin and trapidil on cardiovascular events after acute myocardial infarction. Am J Cardiol. 1999;83(9):1308-1313.
51. Meinertz T, Lehmacher W; Trapidil/ISDN Study Group. Trapidil is as effective as isosorbide-dinitrate for treating stable angina pectoris: a multinational, multicenter, double-blind, randomized study. Clin Res Cardiol. 2006;95(4):217-223.
52. Suzuki S, Sobata E, Iwabuchi T. Prevention of cerebral ischemic symptoms in cerebral vasospasm with trapidil, an antagonist and selective synthesis inhibitor of thromboxane A2. Neurosurgery. 1981;9(6):679-685.
53. Sawada M, Yanamoto H, Nagata I, et al. Prevention of neointimal formation by a serine protease inhibitor, FUT-175, after carotid balloon injury in rats. Stroke. 1999;30(3):644-650.